Valby, Denmark

Ann-Louise Bergstrôm

USPTO Granted Patents = 10 

Average Co-Inventor Count = 12.1

ph-index = 8

Forward Citations = 91(Granted Patents)


Company Filing History:


Years Active: 2019-2023

Loading Chart...
10 patents (USPTO):Explore Patents

Title: Ann-Louise Bergstrøm: Innovator in Synucleinopathy Treatment

Introduction

Ann-Louise Bergstrøm is a prominent inventor based in Valby, Denmark. She has made significant contributions to the field of medical research, particularly in the treatment of synucleinopathies. With a total of 10 patents to her name, her work focuses on developing novel therapeutic agents for neurodegenerative diseases.

Latest Patents

One of her latest patents involves agents, uses, and methods for the treatment of synucleinopathy. This invention relates to novel monoclonal anti-alpha-synuclein antibodies. These antibodies can be utilized for treating various forms of synucleinopathy, including Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease, combined Alzheimer's and Parkinson disease, pure autonomic failure, and multiple system atrophy.

Career Highlights

Ann-Louise Bergstrøm is currently associated with H. Lundbeck A/S, a leading pharmaceutical company specializing in brain diseases. Her innovative research has positioned her as a key figure in the development of treatments for complex neurological conditions.

Collaborations

Throughout her career, Ann-Louise has collaborated with notable professionals in her field, including Pekka Kallunki and Karina Fog. These partnerships have enhanced her research and contributed to the advancement of therapeutic strategies for synucleinopathies.

Conclusion

Ann-Louise Bergstrøm's work exemplifies the impact of innovation in the medical field, particularly in addressing challenging neurodegenerative diseases. Her contributions continue to pave the way for new treatment options that can improve the quality of life for patients suffering from these conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…